These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25981311)

  • 1. The interest in eight new psychoactive substances before and after scheduling.
    Ledberg A
    Drug Alcohol Depend; 2015 Jul; 152():73-8. PubMed ID: 25981311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of 'legal high' packages containing synthetic cathinones.
    Araújo AM; Valente MJ; Carvalho M; Dias da Silva D; Gaspar H; Carvalho F; de Lourdes Bastos M; Guedes de Pinho P
    Arch Toxicol; 2015 May; 89(5):757-71. PubMed ID: 24903018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.
    Helander A; Beck O; Hägerkvist R; Hultén P
    Scand J Clin Lab Invest; 2013 Aug; 73(5):400-6. PubMed ID: 23692208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl analogs on the Swedish webforum flashback: Interest and impact of scheduling.
    Moeller K; Svensson B; Munksgaard R
    Int J Drug Policy; 2021 Jan; 87():103013. PubMed ID: 33181448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current challenges and problems in the field of new psychoactive substances in Germany from a law enforcement perspective.
    Duffert A
    Drug Test Anal; 2014; 6(7-8):876-8. PubMed ID: 24415657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.
    Scherbaum N; Schifano F; Bonnet U
    Pharmacopsychiatry; 2017 May; 50(3):116-122. PubMed ID: 28444659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
    Rychert M; Wilkins C
    Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
    Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
    Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project.
    Helander A; Bäckberg M; Beck O
    PLoS One; 2020; 15(4):e0232038. PubMed ID: 32324788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project.
    Helander A; Bäckberg M; Hultén P; Al-Saffar Y; Beck O
    Forensic Sci Int; 2014 Oct; 243():23-9. PubMed ID: 24726531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
    Rychert M; Wilkins C
    Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations.
    Soussan C; Kjellgren A
    Int J Drug Policy; 2016 Jun; 32():77-84. PubMed ID: 27184218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
    Soussan C; Andersson M; Kjellgren A
    Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A snapshot on NPS in Italy: Distribution of drugs in seized materials analysed in an Italian forensic laboratory in the period 2013-2015.
    Odoardi S; Romolo FS; Strano-Rossi S
    Forensic Sci Int; 2016 Aug; 265():116-20. PubMed ID: 26874736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.